Unique ID issued by UMIN | UMIN000025808 |
---|---|
Receipt number | R000029679 |
Scientific Title | Efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction |
Date of disclosure of the study information | 2017/01/23 |
Last modified on | 2018/01/24 13:48:53 |
Efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction
Efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction
Efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction
Efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction
Japan |
Type 2 diabetes
Endocrinology and Metabolism |
Others
NO
To investigate the efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction
Safety,Efficacy
Change and percent change in AST, ALT, gamma-GTP, and HbA1c from baseline to 52 weeks
1) Change in the following items from baseline to 12 and 24 weeks
- AST, ALT, gamma-GTP, HbA1c
2) Change in the following items from baseline to 12, 24, and 52 weeks
- Fasting plasma glucose, HOMA-beta, HOMA-IR
- Body weight, BMI, Waist circumference, and Blood pressure
- NAFLD fibrosis score, FIB-4 index, FLI
3) Change in the following items from baseline to 24 and 52 weeks
- Type IV collagen 7S domain, Ferritin, M2-BP, hs-CRP
4) Change in IL-6 from baseline to 52 weeks
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Oral administration of 2.5 mg luseogliflozin once a day, pre or post breakfast for 52 weeks
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1) Aged >=20, =<80 at consent
2) Poorly glycemic controlled patients who undergo diet/exercise therapy or treatment with hypoglycemic agents for at least 12 weeks
3) HbA1c >= 6.5 and < 9.5%
4) BMI >= 20 kg/m2
5) Provide written informed consent
6) With hepatic dysfunction (ALT>=31 IU/L)
1) Type 1 diabetes
2) Has history of severe ketosis, diabetic coma, or precoma
3) With severe infection, pre or post surgery, and serious trauma
4) With severe renal dysfunction (eGFR<30 mL/min/1.73m2)
5) Has stroke, myocardial infarction, or other serious cardiovascular complications requiring hospitalization within 6 months
6) Receiving SGLT2 inhibitor
7) Nursing or pregnant or planning to become pregnant
8) Has hypersensitivity to luseogliflozin or any other excipients of luseogliflozin
9) Considered as inadequate by the investigator
50
1st name | |
Middle name | |
Last name | Hiroaki Seino |
Seino Internal Medicine Clinic
Medical director
6-192-2, Kaisei, Koriyama-city, Fukushima, Japan
024-983-1024
kn7jh5@bma.biglobe.ne.jp
1st name | |
Middle name | |
Last name | Hiroaki Seino |
Seino Internal Medicine Clinic
Medical director
6-192-2, Kaisei, Koriyama-city, Fukushima, Japan
024-983-1024
kn7jh5@bma.biglobe.ne.jp
Seino Internal Medicine Clinic
Taisho Toyama Pharmaceutical Co., Ltd.
Profit organization
NO
2017 | Year | 01 | Month | 23 | Day |
Unpublished
Preinitiation
2016 | Year | 12 | Month | 16 | Day |
2017 | Year | 01 | Month | 23 | Day |
2017 | Year | 01 | Month | 23 | Day |
2018 | Year | 01 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029679
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |